Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
Martin Svatoň, Milada Zemanová, Jana Skřičková, et al.
Anticancer Research (2018) Vol. 38, Iss. 12, pp. 6771-6782
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Deniz Can Güven, Taha Koray Şahin, Enes Erul, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 133
Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis
Jing Jin, Lan Yang, Dan Liu, et al.
BMJ Open (2020) Vol. 10, Iss. 6, pp. e035031-e035031
Open Access | Times Cited: 88
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
Martin Svatoň, Milada Zemanová, Petra Zemanová, et al.
Anticancer Research (2020) Vol. 40, Iss. 4, pp. 2209-2217
Open Access | Times Cited: 73
Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis
Hesti Platini, Eric Ferdinand, Kelvin Kohar, et al.
Medicina (2022) Vol. 58, Iss. 8, pp. 1069-1069
Open Access | Times Cited: 53
Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review
Lu Zhang, Wen Zhang, Ziye Li, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 47
Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis
Ke Zhou, Jie Cao, Huahang Lin, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 35
Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
Seigo Minami, Shouichi Ihara, Shouko Ikuta, et al.
World Journal of Oncology (2019) Vol. 10, Iss. 2, pp. 90-100
Open Access | Times Cited: 52
Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab
Mark Stares, Emma Doyle, Sally Chapple, et al.
Lung Cancer (2024) Vol. 189, pp. 107497-107497
Closed Access | Times Cited: 5
Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Huilin Xu, Anbing He, Aihua Liu, et al.
International Immunopharmacology (2019) Vol. 77, pp. 105957-105957
Open Access | Times Cited: 42
Neutrophil–to–Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer
Yuki Murakami, Hiroaki Saito, Shota Shimizu, et al.
Anticancer Research (2019) Vol. 39, Iss. 5, pp. 2583-2589
Open Access | Times Cited: 39
Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review
A. Juarez-Garcia, Ruchika Sharma, Matthias Hünger, et al.
Lung Cancer (2022) Vol. 166, pp. 205-220
Open Access | Times Cited: 21
Albumin–globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer
Yu Nakanishi, Takeshi Masuda, Kakuhiro Yamaguchi, et al.
International Journal of Clinical Oncology (2019) Vol. 25, Iss. 1, pp. 74-81
Closed Access | Times Cited: 30
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Zhibo Zhang, Fan Zhang, Yuan Fang, et al.
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 30
Clinical decision support algorithm based on machine learning to assess the clinical response to anti–programmed death-1 therapy in patients with non–small-cell lung cancer
Beung‐Chul Ahn, Jea-Woo So, Chun-Bong Synn, et al.
European Journal of Cancer (2021) Vol. 153, pp. 179-189
Closed Access | Times Cited: 26
The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
Qianning Zhang, Xiaoling Gong, Lei Sun, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 18
Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma
Sang Youn Hwang, Hyun Young Woo, Jeong Heo, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 838-838
Open Access | Times Cited: 3
Current status of prognostic factors in patients with metastatic renal cell carcinoma
Jun Teishima, Shogo Inoue, Tetsutaro Hayashi, et al.
International Journal of Urology (2019) Vol. 26, Iss. 6, pp. 608-617
Open Access | Times Cited: 26
Association between pretreatment C-reactive protein level and survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Haoyu Wang, Ruiyuan Yang, Ke Zhou, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110937-110937
Closed Access | Times Cited: 8
Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy
Jun Ying, Danfei Zhou, Tongjie Gu, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 25
Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 25, pp. 2567-2578
Open Access | Times Cited: 7
Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis
Haoyu Wang, Cui Li, Ruiyuan Yang, et al.
PLoS ONE (2022) Vol. 17, Iss. 5, pp. e0268288-e0268288
Open Access | Times Cited: 12
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer
Dae Won Kim, Youngchul Kim, Bence Kővári, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 556-556
Open Access | Times Cited: 2
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Bohuslav Melichar
Clinical Chemistry and Laboratory Medicine (CCLM) (2022) Vol. 61, Iss. 5, pp. 906-920
Open Access | Times Cited: 8
The Prognostic Value of Albumin-Globulin Ratio and Eosinophil-Neutrophil Ratio in Patients with Advanced Tumors Undergoing Treatment with PD-1/PD-L1 Inhibitors
Yan Ma, Kun Shang, Shanshan Wu, et al.
Nutrition and Cancer (2022) Vol. 74, Iss. 8, pp. 2815-2828
Closed Access | Times Cited: 7
The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients
Ying Huang, Aizong Shen
Medicine (2020) Vol. 99, Iss. 34, pp. e21718-e21718
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top